Clinical trial · no report yet · Phase 2/Phase 3

A022004

Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer

NCT05710406 ↗
Active, not recruiting
Alliance for Clinical Trials in Oncology
Focused

We haven't built an HCP commentary report on A022004 (encorafenib and cetuximab in Colon Adenocarcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.

Indexed commentary on A022004 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

Channel	Indexed
X threads	8

Indexed todayTypical once built

The trial

ClinicalTrials.gov

Official title: Randomized Trial of Consolidation Targeted Adjuvant Therapy With Encorafenib and Cetuximab Versus Usual Care for Patients With Stage II/III BRAF V600E Colon Cancer
Phase: Phase 2/Phase 3
Status: Active, not recruiting
Conditions: Colon Adenocarcinoma; Microsatellite Stable Colon Carcinoma; Stage IIB Colon Cancer AJCC v8; Stage IIC Colon Cancer AJCC v8; Stage III Colon Cancer AJCC v8
Interventions: Encorafenib; Cetuximab; Biospecimen Collection; Computed Tomography; Magnetic Resonance Imaging; Patient Observation
Arms: Arm I (encorafenib, cetuximab) · Experimental
Arm II (patient observation) · Active comparator
Enrollment: 1
Primary outcomes: Circulating tumor deoxyribonucleic acid (ctDNA) clearance rate (Phase II; ctDNA positive cohort)
tDNA recurrence-free survival rate (ctDNA-RFS) (Phase II; ctDNA negative cohort)
Disease free survival (DFS) (Phase III)
Sponsor: Alliance for Clinical Trials in Oncology with National Cancer Institute (NCI)
Start: Aug 16, 2023
Primary completion: Jun 1, 2034 (estimated)
Results posted: No
Registry record: NCT05710406 · updated Jul 2, 2026